# Clinical Trials to Reduce the Risk of Antimicrobial Resistance

> **NCT01570192** · PHASE2 · TERMINATED · sponsor: **University of Florida** · enrollment: 43 (actual)

## Conditions studied

- Bacterial Pneumonia

## Interventions

- **DRUG:** IV meropenem
- **DRUG:** I.V. Meropenem
- **DRUG:** Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h
- **DRUG:** Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage.
- **DEVICE:** tobramycin nebulization

## Key facts

- **NCT ID:** NCT01570192
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-09
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 43 (ACTUAL)
- **Why stopped:** NIAID terminated the study due to low subject enrollment
- **Last updated:** 2017-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01570192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01570192, "Clinical Trials to Reduce the Risk of Antimicrobial Resistance". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01570192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*